SCHEMBL12897207

SCHEMBL12897207

O=c1oc(-c2ccccn2)nc2cc(Cl)cc(Cl)c12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 5/20 0.59
▸ NPC1 O15118 4/20 0.59
▸ TP53 P04637 4/20 0.59
▸ RAB9A P51151 4/20 0.59
▸ SMN1; SMN2 Q16637 4/20 0.59
▸ KDM4E B2RXH2 3/20 0.59
▸ ALDH1A1 P00352 3/20 0.59
▸ HPGD P15428 3/20 0.59
▸ CYP1A2 P05177 1/20 0.50
▸ CYP2C9 P11712 1/20 0.50
▸ CYP2C19 P33261 1/20 0.50
▸ ELANE P08246 6/20 0.47
▸ PKM P14618 2/20 0.47
▸ CCR1 P32246 1/20 0.46
▸ CCR5 P51681 1/20 0.46
▸ CCR8 P51685 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ GRM5 P41594 2/20 0.43
▸ C1R P00736 1/20 0.43
▸ PBRM1 Q86U86 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12897209 0.85 ELANE (0.66) HSD17B10NPC1TP53RAB9ASMN1; SMN2
SCHEMBL8210841 0.75 ELANE (0.78) ELANEC1R
SCHEMBL12927377 0.75 KDM4E (0.45) HSD17B10NPC1TP53RAB9ASMN1; SMN2
SCHEMBL8215031 0.74 ELANE (0.66) HSD17B10NPC1TP53RAB9ASMN1; SMN2
SCHEMBL8203003 0.74 ELANE (0.63) HSD17B10NPC1TP53RAB9ASMN1; SMN2
SCHEMBL13701235 0.70 KDM4E (0.50) HSD17B10NPC1TP53RAB9ASMN1; SMN2
SCHEMBL13700978 0.70 NPC1 (0.63) HSD17B10NPC1TP53RAB9ASMN1; SMN2
SCHEMBL592611 0.68 HSD17B10 (1.00) HSD17B10NPC1TP53RAB9ASMN1; SMN2
SCHEMBL913970 0.67 KDM4E (0.47) KDM4EALDH1A1ELANEC1RPBRM1
Hydrochloric Acid SCHEMBL2147805 0.66 HSD17B10 (0.96) HSD17B10NPC1TP53RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7879846-B2 e.g. 2-(2-Imidazol-1-yl-pyridin-3-yl)-5-methyl-4H-benz[d][1,3]oxazin-4-one ; neutrophil elastase inhibitor; antiinflammatory agent, respiratory system disorders Kyorin Pharmaceutical Co.., Ltd. (JP) 2011-02-01 — — US disclosed
US-7879846-B2 e.g. 2-(2-Imidazol-1-yl-pyridin-3-yl)-5-methyl-4H-benz[d][1,3]oxazin-4-one ; neutrophil elastase inhibitor; antiinflammatory agent, respiratory system disorders Kyorin Pharmaceutical Co.., Ltd. (JP) 2011-02-01 — — US disclosed
US-20080161290-A1 Serine hydrolase inhibitors KYORIN PHARMACEUTICAL CO., LTD. (JP) 2008-07-03 — — US disclosed
US-20080161290-A1 Serine hydrolase inhibitors KYORIN PHARMACEUTICAL CO., LTD. (JP) 2008-07-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161290-A1 Serine hydrolase inhibitors SERPINB1, ELANE, EPX HSD17B10 323/4885NPC1 1286/4885TP53 3437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback